CIK 0001124105 · Accelerated filer<br>Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 562020050
- Phone
- (858) 284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-15 | USMAN NASSIM Director | Sale 10b5-1 | −20,000 | $17.26 | $345K | 1,636 |
| 2024-03-15 | USMAN NASSIM Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −20,000 | 321,652 | ||
| 2024-01-03 | Ma Songjiang President | Sale 10b5-1 | −833 | $11.85 | $10K | 2,918,467 |
| 2023-11-20 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +3,350,897 | 3,350,897 | ||
| 2023-11-20 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +2,262,755 | 2,262,755 | ||
| 2023-11-20 | Ye Weiguo Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +1,665,115 | 1,665,115 | ||
| 2023-11-20 | Ma Songjiang President | Grant or award · Stock Option (Right to Buy) | +4,510,047 | 4,510,047 | ||
| 2023-11-20 | Chen Ruoyu Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +578,540 | 578,540 | ||
| 2023-11-20 | Wu Charles C Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +170,417 | 170,417 | ||
| 2023-10-31 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +1,866 | 1,866 | ||
| 2023-10-31 | Eastling Thomas Wilson Director | Grant or award · Stock Option (Right to Buy) | +314,652 | 314,652 | ||
| 2023-10-31 | Eastling Thomas Wilson Director | Grant or award · Stock Option (Right to Buy) | +1,866 | 1,866 | ||
| 2023-10-31 | Parry Renate Director | Grant or award · Stock Option (Right to Buy) | +1,866 | 1,866 | ||
| 2023-10-30 | Luo Ying Director | Other acquisition | +2,840,376 | 2,840,376 | ||
| 2023-10-30 | GNI Group Ltd. 10% owner | Other acquisition | +63,588,119 | 64,005,887 |
Page 11 of 11 · 215 trades